Not established No approved personal-use instructions Retatrutide remains investigational
Hester CA, Perri G, Prakash LR, Maxwell JE, Ikoma N, Kim MP, Tzeng CD, Smaglo B, Wolff R, Javle M, Overman MJ, Lee JE, Katz MHG
For example, the phase-3 SURMOUNT-1 trial showed Mayas tirzepatide (Zepbound) led to ~20.9% weight loss vs 3.1% on placebo after 72 weeks ( [18] )
As observed for the -EC and GSH standards, concentrations of 1, 10, 100, and 1000 M showed no adverse effects on cell viability compared to the control
It is used as an injectable medication under the brand names Wegovy, Ozempic, and Rybelsus
Protecting heart health is an important goal